Carregant...
Novel neurosensory testing in cancer patients treated with the epothilone B analog, ixabepilone
Background: We have previously established the recommended phase II dose (RPTD) of ixabepilone as 40 mg/m(2) administered over 1 h repeated every 3 weeks with neuropathy as a cumulative dose-limiting toxicity. We expanded the cohort at the RPTD to include detailed assessment of nerve damage in these...
Guardat en:
| Autors principals: | , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Oxford University Press
2008
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2733111/ https://ncbi.nlm.nih.gov/pubmed/18644829 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdn420 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|